A review in the November 2026 issue of Current Opinion in Urology argues for a structured reassessment when an ED tablet does not help. The authors describe several reasons for an apparent treatment failure and distinguish them from a persistent problem that calls for another approach.
News
An analysis in the November issue of The Journal of Sexual Medicine examines a question that erection trials do not always capture: how intense does orgasm feel? Researchers report improved orgasm-intensity scores with a sildenafil oral film, while stressing that this was an exploratory analysis...
A new analysis from the BETAMI-DANBLOCK trials reports a small, temporary increase in ED among men assigned beta-blockers after a heart attack, without a sustained difference in overall erectile-function scores. The finding complicates the assumption that a heart medicine necessarily explains...
A September report from the American Urological Association revisits a practical decision in testosterone care: which formulation fits the patient? Specialists at the AUA's 2026 meeting argued for oral, topical, injectable, and pellet treatment. The discussion focused on tradeoffs rather than a...
A new comparison of treatments for obesity-related low testosterone finds different strengths for different outcomes. The review does not identify one approach that consistently wins on hormone levels, sexual function, body composition, and metabolic health. For patients, it argues against...
A small randomized trial reports better erection-function scores when men with low vitamin D received supplementation alongside tadalafil. The result concerns a defined group with a documented deficiency. It does not show that vitamin D treats ED in men whose levels already meet their needs.
A study of older European men suggests that measured free testosterone can reveal associations with sexual symptoms that total testosterone alone misses. The research adds a laboratory question to the assessment of low desire and ED, rather than establishing a new treatment threshold for every man.
The SPIRIT trial has added randomized evidence to a difficult question: can selected men with testosterone deficiency receive replacement therapy after prostate cancer surgery? Its results show short-term improvements in several measures of sexual and physical function, alongside a clear limit...
Federal health officials have requested changes to testosterone product labels, including language about age-related hypogonadism and prostate health. The June 18, 2026 announcement changes the regulatory discussion, but it does not remove the need to establish a diagnosis or review treatment risks.
A new analysis of U.S. health records links erectile dysfunction and low testosterone with later cardiometabolic diagnoses. The finding gives men another reason to discuss persistent erection changes as a medical concern, even when their immediate priority involves sex.